Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non–Small-Cell Lung Cancer?

Documenti analoghi

• Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
  di: Jassem, Jacek
  Pubblicazione: (2019)
• Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
  di: Arulananda, Surein, et al.
  Pubblicazione: (2020)
• Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
  di: Lemmon, Christopher, et al.
  Pubblicazione: (2020)
• Neoadjuvant vs. adjuvant chemotherapy in locally advanced non-small cell lung cancer—is timing everything?
  di: Subramanian, Melanie P., et al.
  Pubblicazione: (2019)
• Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
  di: Shepherd, Annemarie F., et al.
  Pubblicazione: (2020)